Company Profile

Selexys Pharmaceuticals Corporation
Profile last edited on: 7/3/19      CAGE: 4KBS9      UEI:

Business Identifier: Therapeutics for treatment of inflammation, thrombosis and metastasis
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

840 Research Parkway Suite 516
Oklahoma City, OK 73104
   (405) 319-8195
Location: Single
Congr. District: 05
County: Oklahoma

Public Profile

In November 2016, it was announced that Novartis had acquired Selexys Pharmaceuticals Corporation. Since 2012, Novartis had had an exclusive right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results from the study will be presented during the Plenary Scientific Session at the 58th American Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, CA. Selexsyz focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases. The firms’ lead program is for a humanized antibody (SelG1) that binds P-selectin with high affinity and specificity and blocks its function. Studies in animal models of SCD have shown that blocking or eliminating P-selectin function has a potential therapeutic effect by preventing vasoocclusion and maintaining normal blood flow. Selexys has been granted Orphan Drug Designation in both the U.S. and Europe for SelG1 in the treatment of sickle cell-related pain crises. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders. In September 2012, Selexys completed a $25 million Series A equity financing led by MPM Capital and entered into an agreement with Novartis Pharmaceuticals whereby Novartis was granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, for up to $665M following the successful completion of a Phase 2 clinical study in patients with sickle cell disease.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $4,390,640
Project Title: Development of an Anti-Psgl-1 Antibody to Treat Crohn's Disease
2014 2 NIH $6,455,701
Project Title: Development of an Anti-P-Selectin Antibody for the Treatment of Sickle Cell Disea
2004 1 NIH $304,843
Project Title: PEGylation of a Glycosulfopeptide Anti-Inflammatory

Key People / Management

  Scott A Rollins -- President and CEO

  Richard Alvarez -- Co-Founder and COO

  Richard D Cummings -- Co-Founder

  David Falconer -- Vice President of Business and Drug Development

  William A Hagstrom -- former President

  Ziad Kawar

  Rodger P McEver -- Co-Founder

  Russell Rother -- Executive Vice President and COO